EUVIMEDEUVIMED entdecken
Open Access

Microenvironment actuated CAR T cells improve solid tumor efficacy without toxicity

Kristen C Vogt iD, Pedro C Silberman iD, Qianqian Lin iD, James E Han, Amy Laflin, Hendryck A Gellineau, Daniel A Heller iD, David A Scheinberg iD

Science Advances · 24.01.2025 · 11 (4)

DOI: 10.1126/sciadv.ads3403 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 24.01.2025. Verfasst von Kristen C Vogt und 7 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Hauptthemen laut MEDLINE: Tumor Microenvironment, Receptors, Chimeric Antigen, Immunotherapy, Adoptive, Neoplasms. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NCI NIH HHS, NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A major limiting factor in the success of chimeric antigen receptor (CAR) T cell therapy for the treatment of solid tumors is targeting tumor antigens also found on normal tissues. CAR T cells against GD2 induced rapid, fatal neurotoxicity because of CAR recognition of GD2 + normal mouse brain tissue. To improve the selectivity of the CAR T cell, we engineered a synthetic Notch receptor that selectively expresses the CAR upon binding to P-selectin, a cell adhesion protein overexpressed in tumor neovasculature. These tumor microenvironment actuated T (MEAT) cells ameliorated T cell infiltration in the brain, preventing fatal neurotoxicity while maintaining antitumor efficacy. We found that conditional CAR expression improved the persistence of tumor-infiltrating lymphocytes because of enhanced metabolic fitness of MEAT cells and the infusion of a less differentiated product. This approach increases the repertoire of targetable solid tumor antigens by restricting CAR expression and subsequent killing to cancer cells only and provides a proof-of-concept model for other targets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor MicroenvironmentReceptors, Chimeric AntigenImmunotherapy, AdoptiveNeoplasmsT-LymphocytesAnimalsMiceHumansCell Line, TumorAntigens, NeoplasmLymphocytes, Tumor-InfiltratingXenograft Model Antitumor AssaysReceptors, Notch

Substanzen

Receptors, Chimeric AntigenAntigens, NeoplasmReceptors, Notch

Autor:innen und Institutionen

  • Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Graduate School of Medical Sciences, Weill Cornell Medicine, New York, NY 10065, USA.
  • Tri-Institutional PhD Program in Chemical Biology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Pharmacology Program, Weill Cornell Medicine, New York, NY 10065, USA.
  • BCMB Program, Weill Cornell Medicine, New York, NY 10065, USA.
  • Meinig School of Biomedical Engineering, Cornell University, Ithaca, NY 14853, USA.

ORCID-Profile: Kristen C Vogt, Pedro C Silberman, Qianqian Lin, Daniel A Heller, David A Scheinberg

Förderung

  • NIGMS NIH HHS
  • NCI NIH HHS
  • NINDS NIH HHS

Zitieren

APA

Vogt, K. C., Silberman, P. C., Lin, Q., Han, J. E., Laflin, A., Gellineau, H. A., Heller, D. A., & Scheinberg, D. A. (2025). Microenvironment actuated CAR T cells improve solid tumor efficacy without toxicity. Science Advances, 11(4). https://doi.org/10.1126/sciadv.ads3403

Vancouver

Vogt KC, Silberman PC, Lin Q, Han JE, Laflin A, Gellineau HA, et al. Microenvironment actuated CAR T cells improve solid tumor efficacy without toxicity. Science Advances. 2025;11(4). doi:10.1126/sciadv.ads3403

BibTeX
@article{Vogt2025,
  author = {Vogt, Kristen C and Silberman, Pedro C and Lin, Qianqian and Han, James E and Laflin, Amy and Gellineau, Hendryck A and Heller, Daniel A and Scheinberg, David A},
  title = {Microenvironment actuated CAR T cells improve solid tumor efficacy without toxicity},
  journal = {Science Advances},
  year = {2025},
  volume = {11},
  number = {4},
  doi = {10.1126/sciadv.ads3403}
}
Kostenlos starten →